Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22338831 | 1.00 | CYP2D6 (0.49) | CYP2D6MEN1CYP2C9CYP2C19KMT2A | |
| SCHEMBL1162118 | 1.00 | CYP2D6 (0.49) | CYP2D6MEN1CYP2C9CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL839858 | 0.98 | CYP2D6 (0.47) | CYP2D6MEN1CYP2C9CYP2C19KMT2A | |
| SCHEMBL5320862 | 0.85 | CYP2D6 (0.46) | CYP2D6MEN1CYP2C9CYP2C19KMT2A | |
| SCHEMBL24875585 | 0.84 | CYP2D6 (0.49) | CYP2D6MEN1CYP2C9CYP2C19KMT2A | |
| SCHEMBL7916228 | 0.84 | CYP2C9 (0.71) | CYP2D6MEN1CYP2C9CYP2C19KMT2A | |
| SCHEMBL27665607 | 0.84 | CYP2C9 (0.49) | CYP2D6MEN1CYP2C9CYP2C19KMT2A | |
| SCHEMBL839118 | 0.84 | KMT2A (0.49) | CYP2D6MEN1CYP2C9CYP2C19KMT2A | |
| SCHEMBL838698 | 0.84 | CYP2D6 (0.49) | CYP2D6MEN1CYP2C9CYP2C19KMT2A | |
| SCHEMBL26664040 | 0.84 | CYP2D6 (0.49) | CYP2D6MEN1CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1886363-A | Amino acids with affinity for the alpha2delta-protein | WARNER LAMBERT CO (US) | 2006-12-27 | — | — | CN | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9629789-B2 | Rosacea treatments using polymetal complexes | OBAGI MEDICAL PRODUCTS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9593138-B2 | Nitrile-containing enzyme inhibitors and ruthenium complexes thereof | WAYNE STATE UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9579332-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9556113-B2 | Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment | THE SOUTH DAKOTA BOARD OF REGENTS (US) | 2017-01-31 | — | — | US | disclosed |
| US-9457035-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-5591851-A | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996026933-A9 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | — | 1996-11-28 | — | — | WO | disclosed |
| WO-1996026933-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1996-09-06 | — | — | WO | disclosed |
| WO-1996023801-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, ITPA | CYP2D6 3806/4885MEN1 3603/4885CYP2C9 4205/4885 |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | CYP2D6 4028/4885MEN1 3266/4885CYP2C9 4109/4885 |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | PIK3CA, TYMP, ITPA | CYP2D6 4028/4885MEN1 3266/4885CYP2C9 4109/4885 |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | CYP2D6 4028/4885MEN1 3266/4885CYP2C9 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.